Format

Send to

Choose Destination
See comment in PubMed Commons below
Mod Rheumatol. 2014 Jan;24(1):42-51. doi: 10.3109/14397595.2013.854051.

Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.

Author information

1
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health , 1-1 Iseigaoka, Yahatanishi-ku, Fukuoka 807-8555 , Japan.

Abstract

OBJECTIVES:

Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA).

METHODS:

Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice.

RESULTS:

At week 24, 20 % of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 % were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 % of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels <1.5 mg/dl (88 %) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 %), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections.

CONCLUSIONS:

Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice.

PMID:
24261758
DOI:
10.3109/14397595.2013.854051
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center